Last Friday, the company announced that the European Medicines Agency conditionally approved vintafolide (brand name Vynfinit), a folate receptor SMDC, as a treatment for platinum-resistant ovarian cancer, as well as two companion imaging agents. In a separate press release the same day, Endocyte announced that Vynfinit showed promise as a potential treatment for NSCLC in a mid-stage trial when used in combination with the chemotherapy drug docetaxel.